Vericel Corp. | Mutual Funds
Mutual Funds that own Vericel Corp.
SPDR S&P Biotech ETF
2,086,699
4.88%
5,367
0.44%
09/06/2018
Vanguard Total Stock Market Index Fund
1,082,480
2.52%
42,220
0%
07/31/2018
iShares Russell 2000 ETF
772,194
1.81%
-411
0.02%
09/06/2018
Vanguard Extended Market Index Fund
581,018
1.36%
0
0.01%
07/31/2018
iShares Russell 2000 Growth ETF
359,883
0.84%
0
0.04%
09/06/2018
Driehaus Micro Cap Growth Fund
314,894
0.74%
59,820
0.78%
06/30/2018
FCP OP Medical BioHe@lth-Trends
249,379
0.57%
76,000
1.74%
11/30/2017
USAA Small Cap Stock Fund
235,549
0.55%
130,719
0.16%
06/30/2018
Russell US Small Cap Equity Fund
214,369
0.5%
214,369
0.12%
04/30/2018
Fidelity Spartan Extended Market Index Fund
202,565
0.47%
0
0.01%
07/31/2018
| Address |
64 Sidney Street
Cambridge Massachusetts 02139
United States
|
|
Employees
|
- |
| Website |
http://www.vcel.com |
| Updated |
07/08/2019 |
| Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio include MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. |
